Isavuconazole is one of 58 small molecule programs targeting Mucormycosis. It is currently in Phase 2.
Indications
Total Trials
Active Trials
Competitors
Pipeline
Competition
34 competitors in Central Nervous System Lymphoma
Rituxan
Idamycin
Tepadina
Brukinsa
Temodar
Trexall
Nublexa
Cytosar
Gazyva
Fludara
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Clinical
Sources